TLC announces first Laser Cataract Surgeries to be performed in Canada

NewsGuard 100/100 Score

TLC Laser Eye Centers is excited to announce the first Laser Cataract Surgeries to be performed in Canada, using an approved femtosecond laser, will take place at TLC's Mississauga center on July 24, 2012. The LenSx Laser is the first femtosecond laser approved by Health Canada for use in cataract surgery.    

LenSx Laser Refractive Cataract Surgery represents a big leap forward in the evolution of cataract and implant surgery. It introduces a blade-free approach to cataract surgery, similar to bladeless-LASIK surgery. With this technology, a cool laser is used to create corneal incisions unlike traditional cataract surgery which utilizes a diamond blade.

Drs. Ike Ahmed and Dean Smith, Co-Medical Directors of TLC Laser Eye Centers Mississauga, will be the first in Canada to perform Laser Cataract Surgeries using a LenSx Laser.

"TLC has had a long history of innovation in refractive surgery," said Dr. Smith. "The LenSx system will allow us to customize each procedure with a greater degree of accuracy than was previously possible. This translates into better clinical outcomes and happier patients."

"We're proud to be the first in Canada to be doing this," added Dr. Ahmed.

George Neal, Chief Executive Officer for TLC had this to say about the new technology, "As North America's leader in cataract and refractive surgery services, TLC is proud to be the first to offer the technology for Laser Cataract Surgery in Canada. Providing the latest technology is just part of our mission to ensure that patients experience the safest surgical procedures with the best visual outcomes possible.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema